Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01117181 · ClinicalTrials.gov registry record · Phase 2
Apathy in Dementia Methylphenidate Trial (ADMET)
A Phase 2 study, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01117181 is a Phase 2 study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 60 participants.
The verdict
NCT01117181, a Phase 2 study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The Apathy in Dementia Methylphenidate Trial (ADMET) is a masked, placebo-controlled trial that will examine the efficacy and safety of methylphenidate for the treatment of clinically significant apathy in patients with Alzheimer's dementia.
Interventions
- DRUG placebo
- DRUG Methylphenidate
- OTHER Psychosocial intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01117181
The ClinicalTrials.gov registry entry for NCT01117181 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins Bloomberg School of Public Health, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01117181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01117181 about?
NCT01117181 is a clinical study titled "Apathy in Dementia Methylphenidate Trial (ADMET)". The Apathy in Dementia Methylphenidate Trial (ADMET) is a masked, placebo-controlled trial that will examine the efficacy and safety of methylphenidate for the treatment of clinically significant apathy in patients with Alzheimer's dementia.
What is the current status of trial NCT01117181?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2010-06. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01117181?
The interventions under investigation include: placebo (DRUG), Methylphenidate (DRUG), Psychosocial intervention (OTHER).
Who is sponsoring clinical trial NCT01117181?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.